Opinion

Video

Clinical Trials and Real-World Data on Brexu-Cel

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Aside from obe-cel’s different design, what are the differences between the dosing and lymphodepletion regimen among brexu-cel, tisa-cel, and obe-cel?
      • Please comment on obe-cel’s double infusion approach.
    • Please review the ZUMA-3 trial study design and key data updates with brexu-cel.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data